How Should We Move the Field of Chemopreventive Agent Development Forward in a Productive Manner?

  • Frank Louis Meyskens
  • Eva Szabo
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 166)


Epidemiologic observations and preclinical experimental investigations suggest that the prevention or reversal of precancers should be an effective strategy in humans to control cancer. Although “proof of principle” has been established in humans, the results of randomized trials have not been confirmatory in most cases. Toxicity in normal or near-normal populations has also been greater than anticipated. We examine the problems associated with testing chemoprevention agents in humans and offer a process and guidelines that may better inform the logical development of this relatively young clinical field.


Natl Cancer Inst Colorectal Adenoma Chemopreventive Agent Epidemiologic Observation Chemoprevention Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alberts DS, Martinez ME, Roe DJ, et al (2000) Lack of effect of high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians’ Network. N Engl J Med 342:1156–1162PubMedCrossRefGoogle Scholar
  2. Armstrong T, Taylor T, Meyskens FL Jr (2003) Point: Surrogate end point biomarkers are likely to be limited in their usefulness in the development of cancer chemoprevention agents against sporadic cancers. Cancer Epidemiol Biomarkers Prev 12:589–592PubMedGoogle Scholar
  3. Baker SG (2000) Identifying combinations of cancer markers for further study as triggers of early intervention. Biometrics 56:1082–1087PubMedCrossRefGoogle Scholar
  4. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F, van Stolk RU (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348:891–899PubMedCrossRefGoogle Scholar
  5. Croghan MK, Aicken MG, Meyskens FL Jr (1991) Dose-related a-difluoromethylornithine (DFMO) ototoxicity (reversible hearing loss). Am J Clin Oncol 14:331–335PubMedGoogle Scholar
  6. Fisher B, Costantino JP, Wickerham DL, Redmond CD, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–1388PubMedCrossRefGoogle Scholar
  7. Fleming TR, DeMets DL (1996) Surrogate end points in clinical trials: are we being misled? Ann Intern Med 125:605–613PubMedGoogle Scholar
  8. Follen M, Meyskens FL Jr, Atkinson EN, Schottenfeld D (2001) Why most randomized phase II cervical cancer chemoprevention trials are uninformative: lessons for the future. J Natl Cancer Inst 93:1293–1296PubMedCrossRefGoogle Scholar
  9. Goodman GE (1992) The clinical evaluation of cancer chemoprevention agents: defining and contrasting phase I, II, and III objectives. Cancer Res 52:2752s–2757sPubMedGoogle Scholar
  10. Herrington DM, Howard TD (2003) Perspective: from presumed benefit to potential harm—hormone therapy and heart disease. N Engl J Med 349:519–545PubMedCrossRefGoogle Scholar
  11. Hong WK, Lippman SM, Itri LM, et al (1990) Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck. N Engl J Med 323:795–801PubMedCrossRefGoogle Scholar
  12. Ioannidis JP, Haidich A, Pappa M, Kokovi S, Tektonida M, Contopoulos-Ioannidis D, Lau JP (2001) Comparison of evidence of treatment effects in randomized and non-randomized studies. J Am Med Assoc 286:821–830CrossRefGoogle Scholar
  13. Kelloff GJ, Johnson JR, Crowell JA, Boone CW, et al (1995) Approaches to the development and the marketing approval of drugs that prevent cancer. Cancer Epidemiol Biomarkers Prev 4:1–10PubMedGoogle Scholar
  14. Kelloff GJ, Sigman CC, Johnson KM, et al (2000) Perspective on surrogate end point in the development of drugs that reduce the risk of cancer. Cancer Epidemiol Biomarkers Prev 9:127–137PubMedGoogle Scholar
  15. Lippman SM, Lee JJ, Karp DD, Vokes EE, Benner SE, Goodman GE, Khuri FR, Marks R, Winn RJ, Fry W, Graziano SL, Gandara DR, Okawara G, Woodhouse CL, Williams B, Perez C, Kim HW, Lotan R, Roth JA, Hong WK (2001) Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst 93:605–618PubMedGoogle Scholar
  16. Meyskens FL Jr (1992a) Biology and intervention of the premalignant process. Cancer Bull 43:475–480Google Scholar
  17. Meyskens FL Jr (1992b) Biomarkers intermediate endpoints and cancer prevention. J Natl Cancer Inst Monogr 13:177–182PubMedGoogle Scholar
  18. Meyskens FL Jr (1998) Chemoprevention of cancer: a reasonable strategy? Recent Results Cancer Res 151:113–121Google Scholar
  19. Meyskens FL Jr (2000a) Cancer prevention in the Year 2025: an anticipation. Eur J Cancer 36:1737–1740PubMedCrossRefGoogle Scholar
  20. Meyskens FL Jr (2000b) Cancer population genetics and tumour prevention: an unfulfilled paradigm. Eur J Cancer 36:1189–1192PubMedCrossRefGoogle Scholar
  21. Meyskens FL Jr (2000c) Criteria for implementation of large and multiagent clinical chemoprevention trials. J Cell Biol 34:115–120Google Scholar
  22. Meyskens FL Jr (2001) Development of difluoromethylornithine and Bowman-Birk inhibitor as chemoprevention agents by assessment of relevant biomarker modulation: some lessons learned. In: Miller B, Bartsch H, Buffeta P, Dragsted L, Varinco H (eds) Biomarkers in Cancer Prevention. IARC Publications, Lyon, pp 49–56Google Scholar
  23. Meyskens FL Jr, Gerner EW (1999) Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res 5:945–951PubMedGoogle Scholar
  24. Meyskens FL Jr, Emerson SS, Pelot D, et al (1994) Dose de-escalation chemoprevention trial of a-difluoromethylornithine in patients with colon polyps. J Natl Cancer Inst 86:1122–1130PubMedGoogle Scholar
  25. Meyskens FL Jr, Gerner E, Emerson S, Pelot D, et al (1998) Effect of α difluoromethylornithine on rectal mucosal levels for polyamines in a randomized, double-blinded trial for colon cancer prevention. J Natl Cancer Inst 90:1212–1218PubMedCrossRefGoogle Scholar
  26. Meyskens FL Jr, Doyle KJ, McLaren CE, Shanks JE (2001) Effects of difluoromethylornithine chemoprevention on audiometry thresholds and otoacoustic emissions. Arch Otolaryngol Head Neck Surg 127:553–558PubMedGoogle Scholar
  27. Omenn GS, Goodman GE, Thronquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL, Valanis B, Williams JH, et al (1996) Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334:1150–1155PubMedCrossRefGoogle Scholar
  28. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348:883–890PubMedGoogle Scholar
  29. Schatzkin A, Lanza E, Corle D, et al (2000) Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study. N Engl J Med 342:1149–1155PubMedCrossRefGoogle Scholar
  30. Sporn MB, Dunlop NM, Newton DL, Smith JM (1976) Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 35:1332–1338PubMedGoogle Scholar
  31. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215–224PubMedCrossRefGoogle Scholar
  32. Viner JL, Umar A, Hawk ET (2002) Chemoprevention of colorectal cancer: problems, progress, and prospects. Gastroenterol Clin North Am 3:971–999Google Scholar
  33. Wang KK, Kim JY (2003) Photodynamic therapy in Barrett’s esophagus. Gastrointest Endosc Clin N Am 13:483–489PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • Frank Louis Meyskens
    • 1
  • Eva Szabo
    • 2
  1. 1.Department of Internal Medicine (Hematology/Oncology) and Chao Family Comprehensive Cancer CenterUniversity of CaliforniaIrvine, OrangeUSA
  2. 2.Division of Cancer PreventionNational Cancer InstituteBethesdaUSA

Personalised recommendations